Pharmamarketeer

FDA Approves Padcev for Treatment of Advanced Urothelial Cancer

Padcev

THURSDAY, Dec. 19, 2019 — Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, has received accelerated approval for the treatment of locally advanced or metastatic urothelial cancer, the U.S. Food and…

Medhc-fases-banner
Advertentie(s)